{"title":"梯瓦收购MicroDose Therapeutx扩大呼吸管道","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1961","DOIUrl":null,"url":null,"abstract":"Teva Pharmaceutical Industries has agreed to acquire MicroDose Therapeutx and its proprietary inhalation technologies for US$40 M upfront and up to US$125 M in post-acquisition milestones. MicroDose’s pipeline of products for lung diseases and infections is led by MDT-637, an inhalable small molecule fusion inhibitor that prevents replication of the respiratory syncytial virus and which is expected to begin Phase II trials later in 2013. The deal complements Teva’s therapeutic focus on respiratory and CNS diseases as part of a revised growth strategy outlined in December 2012.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Teva Expands Respiratory Pipeline with MicroDose Therapeutx Purchase\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I7.1961\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Teva Pharmaceutical Industries has agreed to acquire MicroDose Therapeutx and its proprietary inhalation technologies for US$40 M upfront and up to US$125 M in post-acquisition milestones. MicroDose’s pipeline of products for lung diseases and infections is led by MDT-637, an inhalable small molecule fusion inhibitor that prevents replication of the respiratory syncytial virus and which is expected to begin Phase II trials later in 2013. The deal complements Teva’s therapeutic focus on respiratory and CNS diseases as part of a revised growth strategy outlined in December 2012.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I7.1961\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I7.1961","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Teva Expands Respiratory Pipeline with MicroDose Therapeutx Purchase
Teva Pharmaceutical Industries has agreed to acquire MicroDose Therapeutx and its proprietary inhalation technologies for US$40 M upfront and up to US$125 M in post-acquisition milestones. MicroDose’s pipeline of products for lung diseases and infections is led by MDT-637, an inhalable small molecule fusion inhibitor that prevents replication of the respiratory syncytial virus and which is expected to begin Phase II trials later in 2013. The deal complements Teva’s therapeutic focus on respiratory and CNS diseases as part of a revised growth strategy outlined in December 2012.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
